GSK Names Luke Miels as CEO Designate
GSK has named Luke Miels as CEO Designate. He will take on full responsibilities as Chief Executive Officer and join the Board on January 1, 2026, succeeding Dame Emma Walmsley. Miels, currently GSK’s Chief Commercial Officer, has played a key role in expanding the company’s specialty medicines portfolio, particularly in oncology and respiratory…